The FDA has approved SKYRIZI (risankizumab-rzaa) for treating children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This approval includes a new 55 mg pre-filled syringe designed for weight-based dosing in patients under 40 kg, making SKYRIZI the first IL-23 inhibitor approved in the U.S. for pediatric patients in this weight category. The decision expands treatment options for young patients, supported by clinical trial data showing safety and efficacy similar to adults. AbbVie also offers patient support programs to improve access to the medication.
Shares of AbbVie, Eli Lilly, and Johnson & Johnson are reaching all-time highs, reflecting renewed investor interest in the biopharmaceutical sector. AbbVie's recent announcement to acquire Apogee Therapeutics boosted its stock by 12%. Analysts attri...
Vanguard High Dividend Yield Index Fund ETF (VYM) provides income through dividends from over 500 U.S. stocks, focusing on large, profitable companies like Broadcom and JPMorgan Chase. With a very low expense ratio of 0.04%, nearly all dividends are ...
AbbVie will announce its financial results for the second quarter of 2026 on July 31, before the stock market opens. The company will host a live webcast of its earnings conference call at 8 a.m. Central time, accessible via its Investor Relations we...
AbbVie is gaining investor confidence as its new immunology drugs Skyrizi and Rinvoq show strong revenue growth, offsetting declines from older products like Humira. The company raised its full-year earnings forecast after beating revenue expectation...
BOTOX Cosmetic, under Allergan Aesthetics and AbbVie, announced 250 women entrepreneurs chosen for The Confidence Collective program, offering skill-building, mentorship, and networking. From this group, 20 participants will receive $20,000 grants to...
